To observe the safety and efficacy of Chidamide combined with Linperlisib in the treatment of refractory and relapsed follicular lymphoma.
The patients diagnosed with follicular lymphoma with grade 1-3a, have received at least second-line systemic treatment, and at least one of the first-line treatments includes anti-CD20 monoclonal antibody (anti-CD20 monoclonal antibody monotherapy or combined chemotherapy). If the latest histopathological diagnosis is more than 6 months, a lymph node or tissue puncture or biopsy (resection or coarse needle puncture) must be performed.
Age ≥18 years old, regardless of gender.
The estimated survival time is more than 3 months.
ECOG ≤ 2.
CNS involvement (current or previous).
Clinical evidence of transformation to a more aggressive subtype of lymphoma
Impaired bone marrow function: neutrophils < 1.5× 10*9/L, HB < 80 g/L, PLT < 75×10*9 /L, Impaired liver function, defined as serum total bilirubin > 1.5 x ULN or serum ALT and AST > 2.5x ULN, Patients with liver infiltration by lymphoma, AST and ALT > 5x ULN, Renal glomerular filtration rate (eGFR) < 30 ml/min.
PT INR>1.5ULN or APTT> 1.5 ULN, Serum amylase or lipase > 1ULN.
The First Affiliated Hospital of Xiamen University
Lead sponsor
Fujian Provincial Hospital
Collaborator
Fujian Cancer Hospital
Collaborator
Zhangzhou Affiliated Hospital of Fujian Medical University
Collaborator
Jieyang People's Hospital
Collaborator
Dongguan People's Hospital
Collaborator
Huizhou Municipal Central Hospital
Collaborator
The First Affiliated Hospital with Nanjing Medical University
Collaborator
Sun Yat-sen University
Collaborator
Shanxi Province Cancer Hospital
Collaborator